Safety and efficacy of factor XIa inhibition with milvexian for secondary stroke prevention (AXIOMATIC-SSP): a phase 2, international, randomised, double-blind, placebo-controlled, dose-finding trialMukul Sharma, Graeme J. Hankey, Carlos A. Molina et al.|The Lancet Neurology|2023Cited by 95
Safety and efficacy of GABAA α5 antagonist S44819 in patients with ischaemic stroke: a multicentre, double-blind, randomised, placebo-controlled trialHugues Chabriat, Usman Khan, Sergi Amaro et al.|The Lancet Neurology|2020Cited by 51
ESO NewsSatoshi Shirao, Peter M. Rothwell, Hiroshi Yoneda et al.|Cerebrovascular Diseases|2010Cited by 1
ErratumSatoshi Shirao, Peter M. Rothwell, Hiroshi Yoneda et al.|Cerebrovascular Diseases|2010Cited by 0